Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month

Roivant and Priovant set the list price for their newly approved rare-disease drug Lisraya at $35,000 for a 30-day supply. The announcement is primarily pricing/launch-related with limited immediate indications of broader financial impact.